Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
35.01
-0.26 (-0.74%)
At close: Dec 5, 2025, 4:00 PM EST
35.03
+0.02 (0.06%)
After-hours: Dec 5, 2025, 5:55 PM EST
Assembly Biosciences Revenue
Assembly Biosciences had revenue of $10.79M in the quarter ending September 30, 2025, with 57.62% growth. This brings the company's revenue in the last twelve months to $37.19M, up 31.30% year-over-year. In the year 2024, Assembly Biosciences had annual revenue of $28.52M with 298.16% growth.
Revenue (ttm)
$37.19M
Revenue Growth
+31.30%
P/S Ratio
8.11
Revenue / Employee
$509,466
Employees
73
Market Cap
553.76M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ASMB News
- 25 days ago - Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates - GlobeNewsWire
- 4 weeks ago - Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting® - GlobeNewsWire
- 7 weeks ago - Assembly Biosciences Announces Upcoming Investor Conference Participation - GlobeNewsWire
- 2 months ago - Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe - GlobeNewsWire
- 2 months ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga
- 4 months ago - Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts - Seeking Alpha
- 4 months ago - Assembly Biosciences Announces Pricing of $175 Million in Equity Financings - GlobeNewsWire
- 4 months ago - Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes - GlobeNewsWire